ENTX Share Price | Entera Bio Ltd. Stock Analysis & Recommendation

Q: How big is Entera Bio Ltd.?

Market Cap: As of Jun 18, Entera Bio Ltd. has a market capitalization of 95.00 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Entera Bio Ltd. reported net sales of 0.22 million and a net profit of -10.10 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 8.08 million and total assets of 9.39 million.

Q: What does Entera Bio Ltd. do?

Overview:Entera Bio Ltd. is an Israel-based biotechnology company focused on the oral delivery of large molecules and biologics within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 95.00 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.05 Return on Equity: -52.07% Price to Book: 4.90Contact Details:Address: Kiryat Hadassah, Minrav Building, Fifth Floor JERUSALEM None : 9112002 Tel: 972 2 5327151 Website: http://www.enterabio.com/

Q: Is Entera Bio Ltd. technically bullish or bearish?

As of 9 September 2025, the technical trend for Entera Bio Ltd. has changed from sideways to mildly bearish. The weekly MACD is bearish, and the monthly MACD is mildly bearish, indicating a negative momentum. The daily moving averages also reflect a bearish stance. The Bollinger Bands show a bearish trend on the monthly timeframe. Additionally, the KST and Dow Theory are both mildly bearish on the weekly and monthly charts. The OBV indicates a mildly bearish trend weekly but is bullish monthly, suggesting some divergence in volume trends.In terms of performance, Entera Bio has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -15.09% versus the S&P 500's 12.22%, and a one-year return of -14.29% compared to 17.14% for the index. Overall, the current technical stance is mildly bearish.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

356.05 k

Shareholding (Sep 2025)

FII

1.76%

Held by 6 FIIs

DII

98.2%

Held by 1 DIIs

Promoter

0.00%

How big is Entera Bio Ltd.?

22-Jun-2025

As of Jun 18, Entera Bio Ltd. has a market capitalization of 95.00 million, with net sales of 0.22 million and a net profit of -10.10 million over the last four quarters. The company reported shareholder's funds of 8.08 million and total assets of 9.39 million as of Dec 24.

View full answer

What does Entera Bio Ltd. do?

22-Jun-2025

Entera Bio Ltd. is an Israel-based biotechnology company specializing in the oral delivery of large molecules and biologics. It has a market cap of $95 million and reported a net loss of $3 million in its most recent quarter.

View full answer

Who are in the management team of Entera Bio Ltd.?

22-Jun-2025

As of March 2022, the management team of Entera Bio Ltd. includes Mr. Gerald Lieberman (Independent Chairman), Dr. Spiros Jamas (CEO), and directors Mr. Zeev Bronfeld, Mr. Sean Ellis, Mr. Yonatan Malca, Ms. Faith Charles, and Mr. Gerald Ostrov. They oversee the company's strategic direction and operations.

View full answer

Is Entera Bio Ltd. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Entera Bio Ltd. shows a mildly bearish technical trend, with negative momentum indicators and underperformance compared to the S&P 500, reflecting a year-to-date return of -15.09%.

View full answer

Compare Entera Bio Ltd. with Similar Stocks

Acasti Pharma, Inc.Alzamend Neuro, Inc.Vincerx Pharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 72 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

-70.77%

Price to Book

4.76

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-66.56%

6 Months

-47.47%

1 Year

-58.73%

2 Years

40.45%

3 Years

12.43%

4 Years

-54.78%

5 Years

-36.59%

Entera Bio Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.87%

EBIT Growth (5y)

3.19%

EBIT to Interest (avg)

-10.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.05

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.73%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.86

EV to EBIT

-7.31

EV to EBITDA

-7.34

EV to Capital Employed

-71.88

EV to Sales

73.68

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-52.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.05%)

Foreign Institutions

Held by 6 Foreign Institutions (1.76%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.85% vs -8.33% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-2.60",
          "chgp": "-3.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-2.60",
          "chgp": "-3.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-61,023.80%",
          "chgp": "6,102.38%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.74% vs 32.06% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.50",
          "val2": "-8.90",
          "chgp": "-6.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-8.90",
          "chgp": "-6.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-52,955.80%",
          "val2": "0.00%",
          "chgp": "-5,295.58%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.70

-2.60

-3.85%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.70

-2.60

-3.85%

Operating Profit Margin (Excl OI)

0.00%

-61,023.80%

6,102.38%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -3.85% vs -8.33% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-9.50

-8.90

-6.74%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-9.50

-8.90

-6.74%

Operating Profit Margin (Excl OI)

-52,955.80%

0.00%

-5,295.58%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.74% vs 32.06% in Dec 2023

All Annual Results

Company CV

About Entera Bio Ltd.

Entera Bio Ltd.

Pharmaceuticals & Biotechnology

Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism, osteoporosis and bone healing.

Company Coordinates

Company Details

Kiryat Hadassah, Minrav Building, Fifth Floor JERUSALEM None : 9112002

Tel: 972 2 5327151

http://www.enterabio.com/

Registrar Details

Entera Bio Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Entera Bio Ltd.?

Watch in Real-Time

What does Entera Bio Ltd. do?

Who are in the management team of Entera Bio Ltd.?

Is Entera Bio Ltd. technically bullish or bearish?

Compare Entera Bio Ltd. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Entera Bio Ltd.

Company Coordinates